Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2026-02-12 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
公司章程
Governance Information Classification · 100% confidence The document is titled "章程" which translates to "Articles of Association" or "Company Bylaws." It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, shareholder meetings, and governance rules. It references relevant laws and regulations such as the Company Law of the People's Republic of China, Securities Law, and Shenzhen Stock Exchange rules. The content is focused on the internal rules and governance framework of the company rather than financial results, audit opinions, or announcements. There is no indication that this is an annual report, audit report, earnings release, or any other financial or regulatory filing. Instead, it is a governance document outlining the company's internal rules and structure. Therefore, the appropriate classification is Governance Information (CGR). The document length (15,000 characters) and detailed content support this classification with high confidence.
2026-02-12 Chinese
关于完成《公司章程》备案的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the completion of the filing (备案) of the company's Articles of Association (公司章程) with the relevant market supervision authority. It references prior board and shareholder meetings where amendments were approved and states that the updated Articles have been officially filed. The document is short (1057 characters) and serves as a formal notice of the completion of a regulatory filing related to corporate governance documents. It does not contain financial data, audit information, or detailed report content. It is not a full report but an announcement of a filing completion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-02-12 Chinese
2025年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2025 annual performance forecast (业绩预告) issued by the company, providing estimated net profit ranges and explanations for the expected performance. It explicitly states that the data is preliminary, unaudited, and that the final financial data will be disclosed in the 2025 Annual Report. The document is short (1231 characters) and serves as a forward-looking earnings guidance rather than a full financial report. It does not contain actual financial statements or detailed financial analysis. Therefore, it is best classified as an Earnings Release (ER), which covers initial announcements of periodic financial results or forecasts. FY 2025
2026-01-27 Chinese
关于股票交易异常波动及股票交易严重异常波动的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. regarding abnormal and severely abnormal stock price fluctuations over specific dates in January 2026. It includes detailed explanations about the stock price movements, company self-inspection results, confirmation of no undisclosed material information, risk warnings to investors, and references to regulatory rules from the Shenzhen Stock Exchange. The document does not contain financial statements or detailed financial performance data but serves as a regulatory disclosure about stock trading anomalies and related company statements. It is not a financial report, earnings release, or management discussion but a regulatory announcement about stock price behavior and compliance. Therefore, it fits best under Regulatory Filings (RNS). The document length is 2773 characters, relatively short and focused on disclosure rather than a full report.
2026-01-14 Chinese
关于股票交易异常波动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding abnormal stock price fluctuations of the company Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the investigation and confirmation that no undisclosed material information exists that could explain the stock price movement. It also mentions the scheduled release date of the 2025 annual report but does not contain any financial statements or substantive financial data itself. The document is short (1435 characters) and serves as a regulatory disclosure about stock price abnormality and compliance with disclosure rules. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than a financial report or other specific filing type.
2026-01-12 Chinese
2025年前三季度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an "权益分派实施公告" which translates to "Implementation Announcement of Equity Distribution" for the first three quarters of 2025. It details the dividend distribution plan, including cash dividend per share, the total dividend amount, the record date, and the ex-dividend date. It also references the approval of the profit distribution plan at the 2025 third extraordinary shareholders meeting. The document is an announcement of the implementation of a dividend distribution plan rather than the dividend declaration itself or a full financial report. The document length is 3214 characters, which is relatively short and consistent with an announcement rather than a full report. The content focuses on the dividend payment details and related shareholder information, fitting the definition of a Notice of Dividend Amount (DIV).
2026-01-07 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.